

Enhancing treatment uptake for hepatitis C virus (HCV) infection through high intensity point-of-care HCV testing in prisons in Queensland, Australia

O'Flynn M¹, Young M¹, Nguyen W², Grimstrup D³, Markus C⁴, Matthews S⁴, Williams J⁴, Martinez M⁵, Silk D⁵, Comben S⁵, Davey S⁵, Lloyd A⁵, Cunningham E⁵, Grebely J^{5*}, and O'Loan J^{1*}

¹Kombi Clinic, Brisbane, Australia, ²Hepatitis Queensland, Brisbane, Australia, ³Queensland Injector Health Network (QuIHN), Brisbane, Australia, ⁴Flinders University International Centre for Point-of-Care Testing, Flinders Health and Medical Research Institute, Flinders University, Adelaide, Australia, ⁵The Kirby Institute, UNSW, Sydney, Australia

*contributed equally

Background: Elimination of HCV among people in prison, necessitates phlebotomy and pathology pathways often requiring multiple visits with loss to follow-up. Overcoming these challenges, high intensity onsite point-of-care testing campaigns were initiated. This study evaluated treatment uptake following HCV point-of-care testing campaigns at six prisons in Queensland, Australia.

Methods: HCV testing campaigns included male and female people in prison receiving point-of-care HCV RNA testing across six prisons in Queensland, Australia, including one revisited prison. Between March 2022 and February 2023 testing occurred over a total of 36 days. Project was conducted through partnership with the Queensland Health, Queensland Corrections, Kombi Clinic, community-based organisations, point-of-care quality management providers and research institutions. Participants received onsite point-of-care HCV RNA testing (Xpert HCV Viral Load Fingerstick assay with six Cepheid GeneXpert IV platforms), linkage to nursing/physician care, and HCV treatment. Primary outcome was HCV treatment uptake within four weeks of testing.

Results: Between 28 March 2022 and 10 February 2023, 2,629 people received point-of-care RNA testing, representing 57% (range, 37%-90%) of all people in the prisons at the time. This included 2,301 males (median age, 35 years; 39% Aboriginal and/or Torres Strait Islander; 66% history of injecting drug use) and 328 females (median age 35 years; 50% Aboriginal and/or Torres Strait Islander; 69% history of injecting drug use). HCV RNA prevalence differed between males (22%, 512/2301) and females (4%, 12/328; $p < 0.001$). HCV treatment uptake was similar between males (91%, 464/512) and females (92%, 11/12; $p = 0.902$).

Conclusions: GeneXpert HCV point-of-care testing through large-scale high intensity testing programs within prisons led to high HCV treatment uptake. These campaigns can achieve high coverage rates within correctional environments, facilitating a significant proportion of people to be rapidly tested and coupled with timely delivery of treatment. Collaboration with partners and stakeholders is critical to the success of these campaigns.

Disclosure of Interest Statement: GeneXpert machines and cartridges were provided through the National Australian Hepatitis C Point of Care Testing Program through funding support from the Commonwealth Department of Health, the National Health and Medical Research Council, Cepheid, Gilead Sciences, and AbbVie. Travel grant provided by Gilead Sciences Pty Ltd for Kombi Clinic high intensity testing programs. JG is a consultant/advisor and has received research grants from AbbVie, Cepheid, Gilead, and Merck outside the submitted work.